Grimes & Company Inc. acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 3,193 shares of the biopharmaceutical company’s stock, valued at approximately $226,000.

Several other large investors have also recently added to or reduced their stakes in GILD. Hall Laurie J Trustee boosted its position in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the last quarter. Cable Hill Partners LLC boosted its position in shares of Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. boosted its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the last quarter. Finally, Penserra Capital Management LLC boosted its position in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the last quarter. Hedge funds and other institutional investors own 74.02% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down 0.32% during midday trading on Friday, reaching $72.11. The company’s stock had a trading volume of 6,052,601 shares. The stock has a market capitalization of $94.17 billion, a PE ratio of 7.83 and a beta of 1.21. The company has a 50 day moving average price of $72.61 and a 200-day moving average price of $68.83. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $82.10.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter last year, the company posted $3.08 EPS. The firm’s revenue was down 8.2% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post $8.75 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.88%. Gilead Sciences’s dividend payout ratio is presently 22.58%.

TRADEMARK VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/19/grimes-company-inc-acquires-new-stake-in-gilead-sciences-inc-gild-updated-updated-updated.html.

GILD has been the topic of several analyst reports. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 target price on the stock in a research report on Tuesday, May 2nd. BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Barclays PLC reissued an “overweight” rating and issued a $85.00 price objective (down previously from $90.00) on shares of Gilead Sciences in a research report on Sunday, April 23rd. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price objective on the stock in a research report on Monday, June 26th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $79.00 price target on shares of Gilead Sciences in a research report on Monday, May 15th. Eleven equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $80.31.

In other news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the sale, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The disclosure for this sale can be found here. Insiders sold a total of 206,666 shares of company stock valued at $15,223,184 in the last three months. 1.30% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.